Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

The real drug development delay? Bad communication.

Jonathan Faison first started exploring the biotech space a decade ago. He emphasizes a focus on preserving capital by limiting position sizes and picking stocks that have multiple "irons in the fire" ...

FHLC is the far cheaper option for long-term investors, charging an expense ratio of just 0.08% compared to BBH's 0.35%. FHLC also pays a higher trailing dividend yield of 1.40%, nearly 0.9 percentage ...

2022 has been a terrible, horrible, no good, very bad year for biotech. The industry has suffered from the broader market environment and from some forces specific to biotech. Overall, investors have ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.